It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Interactions between cells and the extracellular matrix, mediated by integrin adhesion complexes, play key roles in fundamental cellular processes, including the sensing and transduction of mechanical cues. Here, we investigate systems-level changes in the integrin adhesome in patient-derived cutaneous squamous cell carcinoma cells and identify the actin regulatory protein Mena as a key node in the adhesion complex network. Mena is connected within a subnetwork of actin-binding proteins to the LINC complex component nesprin-2, with which it interacts and co-localises at the nuclear envelope. Moreover, Mena potentiates the interactions of nesprin-2 with the actin cytoskeleton and the nuclear lamina. CRISPR-mediated Mena depletion causes altered nuclear morphology, reduces tyrosine phosphorylation of the nuclear membrane protein emerin and downregulates expression of the immunomodulatory gene PTX3 via the recruitment of its enhancer to the nuclear periphery. We uncover an unexpected role for Mena at the nuclear membrane, where it controls nuclear architecture, chromatin repositioning and gene expression. Our findings identify an adhesion protein that regulates gene transcription via direct signalling across the nuclear envelope.
Cells transmit mechanical force to the nucleus via the cytoskeleton. Here, the authors reveal a role for the actin regulator Mena in force transmission at the nuclear envelope, where it regulates nuclear architecture, chromatin organization and gene expression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Beernaert, Bruno 2
; Griffith, Billie G. C. 1 ; Loftus, Alexander E. P. 1 ; Kumar, Yatendra 3 ; Wills, Jimi C. 1 ; Lee, Martin 1
; Valli, Jessica 4
; Wheeler, Ann P. 5 ; Armstrong, J. Douglas 6 ; Parsons, Maddy 7
; Leigh, Irene M. 8 ; Proby, Charlotte M. 9
; von Kriegsheim, Alex 1
; Bickmore, Wendy A. 3
; Frame, Margaret C. 1
; Byron, Adam 10
1 University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Oxford, Department of Oncology, Medical Sciences Division, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of Edinburgh, MRC Human Genetics Unit, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 Heriot-Watt University, Edinburgh Super Resolution Imaging Consortium, Institute of Biological Chemistry, Biophysics and Bioengineering, School of Engineering and Physical Sciences, Edinburgh, UK (GRID:grid.9531.e) (ISNI:0000000106567444)
5 University of Edinburgh, Advanced Imaging Resource, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
6 University of Edinburgh, Simons Initiative for the Developing Brain, School of Informatics, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
7 King’s College London, Randall Centre for Cell and Molecular Biophysics, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
8 University of Dundee, Division of Molecular and Clinical Medicine, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876); Queen Mary University of London, Institute of Dentistry, Barts and the London School of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
9 University of Dundee, Division of Molecular and Clinical Medicine, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)
10 University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Manchester, Manchester Academic Health Science Centre, Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)




